WO2019093739A1 - Composition comprenant un extrait de ténébrion meunier en tant que principe actif, destinée à la prévention, à l'atténuation ou au traitement de la stéatose hépatique - Google Patents

Composition comprenant un extrait de ténébrion meunier en tant que principe actif, destinée à la prévention, à l'atténuation ou au traitement de la stéatose hépatique Download PDF

Info

Publication number
WO2019093739A1
WO2019093739A1 PCT/KR2018/013386 KR2018013386W WO2019093739A1 WO 2019093739 A1 WO2019093739 A1 WO 2019093739A1 KR 2018013386 W KR2018013386 W KR 2018013386W WO 2019093739 A1 WO2019093739 A1 WO 2019093739A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
fatty liver
liver disease
alcoholic
brown
Prior art date
Application number
PCT/KR2018/013386
Other languages
English (en)
Korean (ko)
Inventor
채성욱
임아랑
이주영
Original Assignee
한국 한의학 연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국 한의학 연구원 filed Critical 한국 한의학 연구원
Publication of WO2019093739A1 publication Critical patent/WO2019093739A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/20—Animal feeding-stuffs from material of animal origin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L35/00—Food or foodstuffs not provided for in groups A23L5/00 – A23L33/00; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/204—Animal extracts

Definitions

  • the present invention relates to a composition for preventing, ameliorating or treating a fatty liver disease, which comprises an extract of brown gruel as an active ingredient.
  • the death rate of domestic liver disease is very high, 23.5 per 100,000 population.
  • the number of deaths in the 40s is the first (41.1 / 100,000), the second in the 50s (72.4 / 100,000) (10 people / 100,000 people), including liver disease is the leading cause of death in the Korean middle-aged population.
  • liver diseases fatty liver suggests that abnormal fat, which is not present in normal cells, is abnormally deposited in liver cells.
  • abnormal fat which is not present in normal cells, is abnormally deposited in liver cells.
  • triglyceride fatty acid, phospholipid, cholesterol and cholesterol ester are the main components of fat.
  • triglyceride fatty acid, phospholipid, cholesterol and cholesterol ester are the main components of fat.
  • triglyceride fatty acid, phospholipid, cholesterol and cholesterol ester
  • hepatocytes When the fatty liver becomes worse and fat mass in hepatocyte becomes larger, important components of the cells including nucleus are pushed to one side, the function of the hepatocyte is lowered, and the expanded hepatocytes due to the accumulated fat in the cells pressurize the microvascular and lymphatic vessels between the hepatocytes Resulting in obstacles to the circulation of blood and lymph in the liver. In this way, hepatocytes can not properly receive oxygen and nutrient supply, and liver function is deteriorated.
  • Non-alcoholic fatty liver disease is defined as the accumulation of fatty acids in the form of triglycerides in the parenchymal cells of the liver in excess of 5%, not by liver damage caused by alcohol. Pathologically, it is classified as simple steatosis and inflammatory fatty liver disease (steatohepatitis). It can be converted to severe liver disease such as hepatitis, liver fibrosis and cirrhosis when left for a long time. In Korea, the frequency of nonalcoholic liver disease is increasing due to changes in lifestyle.
  • Alcoholic fatty liver disease is caused by excessive alcohol consumption. Individuals have different genetic characteristics and gender. However, alcohol intake of 80g or more per day is very likely to cause liver disease such as alcoholic fatty liver disease. Women are more likely to develop alcoholic liver disease in lesser amounts. Generally, it can be calculated that one cup of shochu, one cup of beer, one cup of wine, and one cup of makkolli contain about 10 g of alcohol. The most mild form of alcoholic fatty liver disease is asymptomatic, but mild hepatic enlargement (greater than normal liver) may cause mild tenderness in the right upper abdomen.
  • the brown goose is 30 ⁇ 38cm in length
  • body color is yellow-green
  • head and chest are yellowish brown.
  • the compound eyes are egg-shaped and lustrous grayish brown.
  • the wings are yellowish brown and longer than the end of the boat but do not fly much. Inhabits grassy areas near rice fields and cultivated areas. It occurs once a year, and it drifts with a bunch of ground in the ground.
  • the alum is wrapped in a thin film of collagen.
  • the full-grown nymphs have a wing crest at the fourth node and a body length of about 30 mm.
  • the use of pesticides as a major pest of rice has decreased, but it is gradually increasing. In 1930, it originated in Hwanghae Province and bought eggs from the government. It is distributed in Korea, Japan, and China.
  • Korean Patent Laid-Open No. 2016-0041115 discloses a composition for preventing or treating diabetes comprising an effective amount of a larva or extract thereof in Korean Patent Application No. 1424125, A composition for treating inflammatory diseases including larva is known, but a composition for preventing, ameliorating or treating a fatty liver disease containing the brown gruel extract of the present invention as an active ingredient is not known.
  • the present invention provides a composition for preventing, ameliorating or treating a fatty liver disease comprising an extract of brown gruel as an active ingredient, wherein the brown gruel extract is a mixture of triglyceride And confirming that there is an effect of inhibiting accumulation, thereby completing the present invention.
  • the present invention provides a health functional food composition for preventing or ameliorating fatty liver disease, which comprises an extract of brown gruel as an active ingredient.
  • the present invention also provides a pharmaceutical composition for the prevention or treatment of fatty liver disease, which comprises an extract of brown gruel as an active ingredient.
  • the present invention also provides a veterinary composition for the prevention or treatment of fatty liver disease in an animal other than a human, which comprises an extract of brown gruel as an active ingredient.
  • the present invention provides a feed additive for preventing or ameliorating fatty liver disease in an animal other than humans, which comprises an extract of brown gruel as an active ingredient.
  • the present invention provides a method for preventing or treating fatty liver disease comprising administering a brown gruel extract to a subject other than a human.
  • the present invention relates to a composition for preventing, ameliorating or treating a fatty liver disease comprising an extract of brown gruel as an active ingredient. Since the brown gruy extract as an active ingredient of the present invention is a raw material known to be edible, it has no side effects and toxicity , because liver cancer cell line (HepG 2) reduction in the accumulation of triglycerides effectively, the composition of the present invention may be useful as a functional food, a drug, or a feed additive for the prevention, improvement or treatment of fatty liver disease.
  • HepG 2 liver cancer cell line
  • liver cancer cell line (HepG 2) on oleate and palmitate is 2: 1 concentration ratio after the process the free fatty acids (FFA) and mealworm extract (Cu) of a mixture of 1.0mM, fat absorption (lipid uptake) .
  • FFA free fatty acids
  • Cu mealworm extract
  • #### showed a statistically significant increase in the fat absorption rate in the group treated with free fatty acids compared with the control group (p ⁇ 0.0001), while * and ** indicate that the brown of the present invention
  • the absorption of free fatty acids in the sorghum extract-treated group was statistically significantly decreased.
  • the * indicates p ⁇ 0.05 and ** indicates p ⁇ 0.01.
  • FIG. 2 shows the results of (A), (B), (C), (C) and (C) (HF + Mi), which was administered with milk fat extract (100 mg / kg / day) as a positive control with high fat diets, and the brown gruel extract administered group (HF + Cu) And (B) the above tissues are shown as oil droplet staining results (above) and their graphs (below).
  • P ⁇ 0.01 was found to be a statistically significant increase in the liver weight of the high-fat diet group compared to the normal group, and ** was higher in the high fat diet group compared to the control group of the brown goat extract- The statistically significant decrease in weight was p ⁇ 0.01.
  • FIG. 3 shows the cell viability (%) after treatment of hepatocellular carcinoma cell line (HepG 2 ) with ethanol and brown goat extract.
  • the cell survival rate of the group was statistically significantly increased, ** is p ⁇ 0.01 and *** is p ⁇ 0.001.
  • FIG. 4 shows the results of examining the expression level of Caspase-3 after treatment of hepatocellular carcinoma cell line (HepG 2 ) with ethanol and brown goat extract.
  • the expression level of Caspase-3 in the ethanol-treated group was significantly higher than that in the control (p ⁇ 0.0001), and **** was significantly higher than that of the control group
  • the expression level of caspase-3 in the treatment group was statistically significantly decreased, and p ⁇ 0.0001.
  • FIG. 5 shows the result of confirming whether the brown goat's extract (Cu) of the present invention reduces ALT increase in the blood by the high fat diet.
  • Mi was a positive control group, which received milk-thirst extract (100 mg / kg / day) with high fat diet. (P ⁇ 0.001) and *** was significantly higher than that of the control group (control group) compared to that of the control group (control group), the brown goat extract treatment group of the present invention or the positive control group , which is a statistically significant decrease in the ALT value of the in-milk-thistle extract-treated group, is p ⁇ 0.001.
  • FIG. 6 shows the result of confirming whether the brown gruel extract (Cu) of the present invention reduces the increase of total cholesterol (TC) in the blood by the high fat diet.
  • Mi was a positive control group, which received milk-thistle extract (100 mg / kg / day) with high fat diet.
  • P ⁇ 0.001, ** and **** were higher than those of the control group (control group), and those of the control group (control group) were significantly higher than those of the control group
  • the total cholesterol in the blood of the extract-treated group or the milk-treated cholesterol extract group, which is a positive control group was statistically significantly decreased, ** is p ⁇ 0.01 and **** is p ⁇ 0.0001.
  • FIG. 7 shows the result of confirming whether the brown gruel extract (Cu) of the present invention reduces the glucose increase in the blood due to the high fat diet.
  • Mi was a positive control group, which received milk-thistle extract (100 mg / kg / day) with high fat diet.
  • ### showed a statistically significant increase in the glucose content of the high-fat diet group compared to the control group (p ⁇ 0.001), ** indicates that the glucose content of the brown goat extract-treated group of the present invention Statistically significant decrease, p ⁇ 0.01.
  • FIG. 8 shows the results of confirming whether the brown gruel extract (Cu) of the present invention reduces the fat droplets of liver tissue formed by high fat diets (HFD).
  • Mi was a positive control group, which received milk-thistle extract (100 mg / kg / day) with high fat diet.
  • A is a liver tissue of a normal control group
  • B is a liver tissue of a high fat diet group
  • C is a liver tissue of a high fat fat diet group and a positive control milk group
  • the liver tissue of the brown gruel extract administration group of the present invention is a positive control group, which received milk-thistle extract (100 mg / kg / day) with high fat diet.
  • the present invention relates to a health functional food composition for preventing or ameliorating fatty liver disease, which comprises an extract of brown gruel as an active ingredient.
  • the brown gutter extract may be prepared by a method including, but not limited to, the following steps:
  • step (3) The step of extracting the filtered extract of step (2) by concentration under reduced pressure and drying.
  • the extraction solvent is preferably selected from water, a C 1 -C 4 lower alcohol or a mixture thereof, more preferably ethanol, even more preferably 70% (v / v) ethanol But is not limited thereto.
  • any conventional method known in the art such as filtration, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction may be used.
  • the extraction solvent is preferably added in an amount of 1 to 20 times, preferably 5 to 15 times, the weight of the dried brown gruel.
  • the extraction temperature is preferably 4 to 50 DEG C, but is not limited thereto.
  • the extraction time is preferably 0.5 to 10 hours, more preferably 0.5 to 5 hours, most preferably 1 hour, but not always limited thereto.
  • the drying is preferably performed under reduced pressure, vacuum drying, boiling, spray drying or freeze drying, but not always limited thereto.
  • the fatty liver disease is non-alcoholic or alcoholic simple fatty liver; Non-alcoholic or alcoholic fatty liver disease; And non-alcoholic or alcoholic cirrhosis, but is not limited thereto.
  • the brown gruel extract is characterized by reducing the content of triglyceride in liver tissue, reducing the content of total triglyceride in liver tissue and decreasing lipid uptake.
  • the health functional food may be prepared by adding the composition of the present invention to a food for the purpose of preventing or ameliorating fatty liver disease.
  • the health functional food is not particularly limited, and may be a health functional food, a nutritional supplement, but it can be any type of food such as pharmafood, health food, nutraceutical, designer food, food additive, etc.
  • the food can be meat, sausage, bread, chocolate, candy, snack, confectionery, , Other noodles, gums, dairy products including ice cream, various soups, drinks, tea, drinks, alcoholic beverages and vitamin complexes.
  • the method of adding is appropriately used according to a conventional method, and the amount to be added can be suitably determined according to the intended use (prevention, health or therapeutic treatment).
  • composition of the present invention may further include various components other than the active component.
  • the various components may be various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, Salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks and the like. It may also contain flesh for the production of natural fruit juices, fruit juice beverages and vegetable beverages to add palatability and / or functionality, and these ingredients may be used independently or in combination.
  • the present invention relates to a pharmaceutical composition for preventing or treating fatty liver disease, which comprises an extract of brown gruel as an active ingredient.
  • the fatty liver disease is a non-alcoholic or alcoholic simple fatty liver; Nonalcoholic or alcoholic fatty liver disease; And non-alcoholic or alcoholic liver cirrhosis, but is not limited thereto.
  • the pharmaceutical compositions of the present invention may comprise a pharmaceutically acceptable carrier.
  • the pharmacologically acceptable carrier to be contained in the pharmaceutical composition of the present invention is one which is usually used at the time of formulation and includes saline, sterilized water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, But are not limited to, lactose, sucrose, sucrose, sorbitol, mannitol, starch, acacia, calcium phosphate, alginate, gelatin, calcium calcium, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, syrup, methylcellulose, methylhydroxybenzoate, Hydroxybenzoate, talc, magnesium stearate, and mineral oil, but the present invention is not limited thereto.
  • the pharmaceutical composition of the present invention may further comprise at least one auxiliary selected from an antioxidant, a buffer, a bacteriostat, a diluent, a surfactant, a binder, a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifying agent, .
  • at least one auxiliary selected from an antioxidant, a buffer, a bacteriostat, a diluent, a surfactant, a binder, a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifying agent, .
  • the pharmaceutical composition of the present invention can be administered orally or parenterally, and is preferably administered orally.
  • the appropriate dosage of the pharmaceutical composition of the present invention may vary depending on such factors as formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, route of administration, excretion rate, .
  • the dosage of the pharmaceutical composition of the present invention is preferably 0.001-100 mg / kg on an adult basis.
  • the pharmaceutical composition of the present invention may be formulated into a unit dosage form by using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by those having ordinary skill in the art to which the present invention belongs. Or by intrusion into a multi-dose container.
  • the formulations may be in the form of solutions, suspensions, syrups or emulsions in oils or aqueous media, or in the form of excipients, powders, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
  • the present invention also relates to a veterinary composition for the prevention or treatment of fatty liver disease in an animal other than humans, which comprises an extract of brown gruel as an active ingredient.
  • the veterinary composition comprising the brown gruel extract of the present invention may further comprise suitable excipients and diluents according to conventional methods.
  • excipients and diluents that can be included in the veterinary composition containing the brown gutter extract of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin , Calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, cetanol, stearyl alcohol, Paraffin, sorbitan monostearate, polysorbate 60, methylparaben, propylparaben, and mineral oil.
  • the veterinary composition comprising the brown gruel extract according to the present invention may further contain a filler, an anti-coagulant, a lubricant, a wetting agent, a spice, an emulsifier, an antiseptic, etc.
  • the veterinary composition according to the present invention may further comprise May be formulated using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient, and the formulations may be formulated as powders, granules, tablets, capsules, suspensions, emulsions, solutions, syrups, aerosols, Soft or hard gelatine capsules, suppositories, sterile injectable solutions, sterile external preparations, and the like.
  • the veterinary composition according to the present invention may vary depending on the age, sex, and body weight of the animal, but may be administered in an amount of 0.1 to 100 mg / kg once or several times a day.
  • the dosage may vary depending on the route of administration, Sex, weight, age, and the like. Thus, the dosage amounts are not intended to limit the scope of the invention in any manner.
  • the present invention also relates to a feed additive for preventing or ameliorating fatty liver disease in an animal other than a human, which comprises an extract of brown gruel as an active ingredient.
  • the feed additive may be in the form of a high concentrate, powder or granulate containing from 20 to 90% by weight of brown gruel extract.
  • the feed additive of the present invention can be used as a feed additive containing a phosphate such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid, or organic acids such as sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate (polymerized phosphate), polyphenol, catechin, Natural antioxidants such as tocopherol, rosemary extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, and phytic acid may be further included.
  • a phosphate such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid, or organic acids such as sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate (polymerized phosphate), polyphenol, catechin, Natural antioxidants such as tocopherol, rosemary extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, and phytic acid may be further included
  • the animal feed additive containing the brown goat's extract of the present invention and the feed comprising the animal feed additive can be supplemented with amino acids, inorganic salts, vitamins, antibiotics, antimicrobials, antioxidants, antifungal enzymes, digestion and absorption enhancers, growth promoters, And the like.
  • the feed additive may be administered alone to the animal in combination with other feed additives in the edible carrier.
  • the feed additives can also be easily administered as top dressing or they can be mixed directly with the animal feed or separately from the feed, in separate oral formulations, by injection or transdermal, or in combination with other ingredients.
  • a single daily dose or a divided daily dose can be used as is well known in the art.
  • the dosage form of the extract may be prepared in an immediate release or sustained release formulation in combination with a non-toxic pharmaceutically acceptable food carrier.
  • Such edible carriers may be solid or liquid, for example, corn starch, lactose, sucrose, soy flakes, peanut oil, olive oil, sesame oil and propylene glycol.
  • the dosage form of the extract may be a tablet, capsule, powder, troche or emulsion or top-dressing in finely divided form.
  • a liquid carrier it may be in the form of a soft gelatin capsule, or a syrup or liquid suspension, emulsion or solution.
  • the dosage form may contain adjuvants such as preservatives, stabilizers, wetting or emulsifying agents, solution promoting agents and the like.
  • the animal feed in which the brown gruel extract is included as a feed additive can be any protein-containing organic gut that is commonly used to meet the dietary needs of an animal. These protein-containing flours usually consist mainly of corn, soy flour or corn / soy flour mix.
  • the feed additive may be added to the animal feed by immersion, spraying or mixing.
  • the veterinary composition or feed additive of the present invention can be applied to the companion animal's diet.
  • the present invention also relates to a method for preventing or treating fatty liver disease comprising administering a brown gruel extract to a subject other than a human.
  • Such an individual includes all animals, including those with a possibility of fatty liver disease, including those suffering from fatty liver disease.
  • the dried brown powdery mildew was refluxed for 3 hours using 70% (v / v) ethanol.
  • a 70% (v / v) ethanol extract was obtained and distilled under reduced pressure to prepare a brown goat ethanol extract.
  • Liver cancer cell line (HepG 2) were purchased from ATCC (American Type Culture Collection). Were cultured in the DMEM-F12 containing the streptomycin (Dulbecco's modified Eagle's medium) medium-liver cancer cell line (HepG 2) is 10% FBS, 1% penicillin. The cells were cultured in a 5% CO 2 incubator at 37 ° C, and the cultured cells were tested by dividing a certain number of cells (3 ⁇ 10 4 cells / 500 ⁇ l well) into 24-well plates.
  • streptomycin Dulbecco's modified Eagle's medium
  • a 0.1 M NaOH solution was used as a solvent at 70 ⁇ C, filtered using a 0.2 ⁇ filter, and then sterilized.
  • the concentration of each fatty acid prepared in (1) above was measured using a 5% (w / v) BSA solution containing no free fatty acid dissolved in the tertiary distilled water prepared in (2) 10 ml of a fatty acid storage solution was prepared so as to be 5 mM.
  • 100 ⁇ l of palmitate and 100 mM of the olate storage solution prepared in (1) above were mixed with 165 ⁇ l (1.65 mM) of palmitate and 330 ⁇ l (3.3 mM) of oleate and 9505 ⁇ l of 5% w / v) dropwise dropwise to the BSA solution (vortexing). Thereafter, the mixture was cooled to room temperature and then filtered with a 0.2 ⁇ m filter (the mixed solution was stable at -20 ° C. for 3 to 4 weeks).
  • Oil red O staining was performed to determine whether the brown goat extract (Cu) reduced the lipid accumulation in liver tissues due to high fat diets. Lipids are stained red by Oil red O staining method.
  • the lipid accumulation increased by the high fat diet was reduced by the brown goat extract (Cu), and the liver tissue protective effect was confirmed.
  • liver weight increase due to fat accumulation of liver tissue was statistically decreased by brown goat extract (Cu).
  • brown gruel extract (Cu) of the present invention reduced the content of ALT, total cholesterol (TC) and glucose in the blood increased by the high fat diet.
  • H & E staining was performed to determine if the brown goat extract (Cu) of the present invention reduced lipid accumulation in the liver by high fat diet.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Animal Husbandry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Insects & Arthropods (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition comprenant un extrait de ténébrion meunier en tant que principe actif pour la prévention, l'atténuation ou le traitement de la stéatose hépatique. Il a été découvert qu'un extrait de ténébrion meunier, qui est un principe actif de la présente invention, induit efficacement une absorption de graisse à partir d'une lignée cellulaire du cancer du foie (HepG2) et a pour effet de réduire les lipides dans les tissus du foie. Par conséquent, la composition de la présente invention peut être avantageuse en tant qu'aliment fonctionnel de santé, produit de médicament ou complément alimentaire pour la prévention, l'atténuation ou le traitement de la stéatose hépatique.
PCT/KR2018/013386 2017-11-08 2018-11-06 Composition comprenant un extrait de ténébrion meunier en tant que principe actif, destinée à la prévention, à l'atténuation ou au traitement de la stéatose hépatique WO2019093739A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170147735A KR20190052233A (ko) 2017-11-08 2017-11-08 갈색거저리 추출물을 유효성분으로 포함하는 지방간 질환의 예방, 개선 또는 치료용 조성물
KR10-2017-0147735 2017-11-08

Publications (1)

Publication Number Publication Date
WO2019093739A1 true WO2019093739A1 (fr) 2019-05-16

Family

ID=66439229

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/013386 WO2019093739A1 (fr) 2017-11-08 2018-11-06 Composition comprenant un extrait de ténébrion meunier en tant que principe actif, destinée à la prévention, à l'atténuation ou au traitement de la stéatose hépatique

Country Status (2)

Country Link
KR (1) KR20190052233A (fr)
WO (1) WO2019093739A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102283749B1 (ko) * 2019-11-13 2021-08-02 재단법인 순천바이오헬스케어연구센터 갈색거저리 유충 발효 추출물의 표준품 분석 방법
KR102407946B1 (ko) * 2020-04-23 2022-06-13 씨제이제일제당 (주) 풍뎅이 유충 또는 이의 추출물을 유효성분으로 포함하는 배변 기능 개선용 조성물
KR102441312B1 (ko) 2020-07-07 2022-09-08 중앙대학교 산학협력단 키누렌산을 포함하는 지방간 질환의 예방 또는 치료용 조성물
KR102566370B1 (ko) * 2022-10-11 2023-08-11 한국 한의학 연구원 콩 추출물을 유효성분으로 함유하는 지방간 질환의 예방, 개선 또는 치료용 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140060426A (ko) * 2012-11-09 2014-05-20 대한민국(농촌진흥청장) 갈색거저리 유충을 포함하는 염증성 질환 치료용 조성물
KR20140065489A (ko) * 2012-11-09 2014-05-30 동아대학교 산학협력단 갈색거저리 추출물을 포함하는 치매 예방 또는 치료용 조성물
KR20160041115A (ko) * 2014-10-06 2016-04-18 대한민국(농촌진흥청장) 갈색거저리 유충 또는 이의 추출물을 유효성분으로 포함하는 당뇨 예방 또는 치료용 조성물
KR20160041138A (ko) * 2014-10-06 2016-04-18 대한민국(농촌진흥청장) 갈색거저리 유충의 추출물 또는 갈색거저리 유충의 현탁액을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물
KR101734067B1 (ko) * 2015-11-10 2017-05-12 대한민국(농촌진흥청장) 갈색거저리를 이용한 곤충고기 조성물 및 이의 제조방법
KR101752253B1 (ko) * 2015-11-10 2017-07-04 대한민국(농촌진흥청장) 갈색거저리를 이용한 곤충어묵 조성물 및 이의 제조방법

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140060426A (ko) * 2012-11-09 2014-05-20 대한민국(농촌진흥청장) 갈색거저리 유충을 포함하는 염증성 질환 치료용 조성물
KR20140065489A (ko) * 2012-11-09 2014-05-30 동아대학교 산학협력단 갈색거저리 추출물을 포함하는 치매 예방 또는 치료용 조성물
KR20160041115A (ko) * 2014-10-06 2016-04-18 대한민국(농촌진흥청장) 갈색거저리 유충 또는 이의 추출물을 유효성분으로 포함하는 당뇨 예방 또는 치료용 조성물
KR20160041138A (ko) * 2014-10-06 2016-04-18 대한민국(농촌진흥청장) 갈색거저리 유충의 추출물 또는 갈색거저리 유충의 현탁액을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물
KR101734067B1 (ko) * 2015-11-10 2017-05-12 대한민국(농촌진흥청장) 갈색거저리를 이용한 곤충고기 조성물 및 이의 제조방법
KR101752253B1 (ko) * 2015-11-10 2017-07-04 대한민국(농촌진흥청장) 갈색거저리를 이용한 곤충어묵 조성물 및 이의 제조방법

Also Published As

Publication number Publication date
KR20190052233A (ko) 2019-05-16

Similar Documents

Publication Publication Date Title
WO2019093739A1 (fr) Composition comprenant un extrait de ténébrion meunier en tant que principe actif, destinée à la prévention, à l'atténuation ou au traitement de la stéatose hépatique
US20100105766A1 (en) Composition for inhibition or prevention of bone density reduction
KR101661145B1 (ko) 백편두 추출물을 유효성분으로 포함하는 비알콜성 지방간질환의 예방 또는 개선용 조성물
KR20210122167A (ko) 해당화 추출물을 유효성분으로 포함하는 여성 폐경기 증후군 예방, 개선 또는 치료용 조성물
KR102085577B1 (ko) 쌍별귀뚜라미 추출물을 유효성분으로 포함하는 지방간 질환의 예방, 개선 또는 치료용 조성물
KR102041852B1 (ko) 벼메뚜기 추출물을 유효성분으로 포함하는 지방간 질환의 예방, 개선 또는 치료용 조성물
WO2020091265A1 (fr) Composition comprenant un extrait de sureau comme composant actif pour prévenir ou traiter le syndrome climatérique masculin ou réduire ses symptômes
KR101913828B1 (ko) 지초 추출물을 유효성분으로 포함하는 근줄기세포로부터 근육세포로의 분화 촉진용 조성물, 근력 약화 관련 질환의 예방 또는 치료용 약제학적 조성물 및 운동수행 능력 향상용 건강기능식품 조성물
KR101326870B1 (ko) 천연물 추출물 또는 이의 분획물을 유효성분으로 포함하는, 급성신부전의 예방 또는 치료용 약학적 조성물
WO2020122373A1 (fr) Composition comprenant un extrait de glycyrrhiza uralensis en tant que principe actif pour la prévention, l'atténuation ou le traitement du syndrome d'hypogonadisme d'apparition tardive
KR102247702B1 (ko) 위염 또는 소화성궤양 예방 또는 치료용 조성물
WO2019083264A1 (fr) Composition pour prévenir, soulager ou traiter des maladies du foie, contenant un produit fermenté d'extrait de germe de ginseng vieilli en tant que substance active
US20230000940A1 (en) Composition for prevention or treatment of Porcine epidemic diarrhea virus infection comprising curcuminoid and licorice extracts or fraction thereof
WO2012134252A2 (fr) Composition pour le traitement du cancer du rein et aliment fonctionnel contenant un extrait de semence de cannabis
KR101692604B1 (ko) 저속으로 추출한 석류주스를 유효성분으로 포함하는 간 기능 개선용 조성물
KR101392715B1 (ko) 의이인탕을 유효성분으로 함유하는 비만의 예방, 개선 또는 치료를 위한 조성물
WO2019004734A2 (fr) Composition pour la prévention, le soulagement ou le traitement de la stéatose hépatique, comprenant un extrait d'oxya chinensis en tant qu'ingrédient actif
WO2019004733A2 (fr) Composition pour la prévention, le soulagement ou le traitement de la stéatose hépatique, comprenant un extrait de gryllus bimaculatus en tant qu'ingrédient actif
KR100539457B1 (ko) 괴각 추출물을 포함하는 고지혈증, 동맥경화증 및지방간의 예방 및 치료용 조성물
WO2021020857A1 (fr) Utilisation d'une composition destinée à la prévention, au soulagement ou au traitement de troubles de perte osseuse, contenant des extraits de reynoutria japonica et de cassiae cortex interior
KR20190083071A (ko) 모과나무 잎 추출물을 유효성분으로 함유하는 대사성 질환의 예방, 개선 또는 치료용 조성물
WO2022098192A1 (fr) Composition pour la prévention ou le traitement de la cachexie comprenant un extrait complexe de plantes médicinales
WO2023008771A1 (fr) Composition destinée à prévenir, à soulager ou à traiter des troubles métaboliques, comprenant un extrait de passiflora caerulea
WO2023224305A1 (fr) Composition destinée à prévenir, atténuer ou traiter l'arthrite et la douleur articulaire, comprenant comme principe actif un extrait de lysimachia mauritiana
WO2012093917A2 (fr) Composition comprenant de l'extrait de tussalingo farafara l. et aliment santé fonctionnel

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18876628

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18876628

Country of ref document: EP

Kind code of ref document: A1